Oxular’s development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and aged related macular degeneration, plus programs for rare and orphan conditions, including ocular cancers, and delivery of gene therapy.

Our approach aims to minimize frequency of treatments, improve delivery, and reduce side effects, while increasing therapeutic effectiveness.